{"schema":"sb.node.v1","id":"sb:e/e20001c47e40d4b109d5f837","kind":"entity","label":{"text":"immunotherapy","locale":"en"},"identity":{"anchor":"label:en:immunotherapy","strength":"label"},"asOf":{"knowledgeCutoff":"2026-11-02T23:20:37.552024+00:00","releaseId":"sb-bd2d22fc815d","snapshot":"deploy 3ac6191ad84a7bf597407804589a9c6ace5a0b33"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":808,"separatePublishers":172,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.489,"named":395,"of":808,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn only from rows whose own title or URL names the subject (the entity graph's subject gate)","blind":["only 49% of the 808 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"canonical","kind":"legacy","kindBasis":"seed","reason":"entity graph provenance 'curated'; part of the hand-written seed vocabulary that predates machine promotion; no receipt exists","policy":"promotion (seed vocabulary; no receipt)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-11","to":"2026-11-01","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.053: about 95% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology","pubmed_targeted"],"activeDays":150,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":10,"byKind":{"observation":10},"withheld":{"state":"withheld","count":2,"reason":"2 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/503156ea1a32b4fd31b3fc08","kind":"observation","label":"Tech Times · 2026-11-01 · FDA Clears Voceryq as First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis","url":"https://www.techtimes.com/articles/329812/20261031/fda-clears-voceryq-first-plasmid-dna-immunotherapy-recurrent-respiratory-papillomatosis.htm","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/e2f32fb953b9c62e3e25d0af","kind":"observation","label":"Los Angeles Times · 2026-10-30 · Your last-minute guide to Proposition 38: Research funding for immunology, immunotherapy","url":"https://www.latimes.com/california/story/2026-10-30/2026-california-election-proposition-38-immunology-last-minute-voter-guide","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/524947622e43cfcd37f75a31","kind":"observation","label":"Seoul Economic Daily · 2026-10-30 · Samsung Bioepis Seeks U.S. Approval for Keytruda Biosimilar","url":"https://en.sedaily.com/finance/2026/10/30/samsung-bioepis-seeks-us-approval-for-keytruda-biosimilar","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/df2b01673a9c64984dda61ce","kind":"observation","label":"Pharmacol Res · 2026-10-30 · Repurposing the orphan drug nitisinone synergizes with sorafenib to sensitize immunotherapy-refractory MSS-CRC via metabolic stress-driven STING activation.","url":"https://doi.org/10.1016/j.phrs.2026.109724","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/16bfa20f6a66cd591a84ccaa","kind":"observation","label":"ascopost.com · 2026-10-30 · OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?","url":"https://ascopost.com/news/october-2026/optitrop-lung06-a-potential-alternative-to-chemotherapy-in-advanced-pd-l1-negative-nsclc/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/f8a0216faa81360144f64e85","kind":"observation","label":"an unnamed outlet · 2026-10-30 · INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) |…","url":"https://www.stocktitan.net/news/INO/inovio-announces-fda-accelerated-approval-of-voceryqtm-an-6o64cas5rrns.html","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/bd2631eecb459dc67a0a6e65","kind":"observation","label":"FDA · 2026-10-30 · FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis","url":"http://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/d45a03bb82b9ddd0ef61c60e","kind":"observation","label":"Medical Xpress · 2026-10-29 · Researchers identify critical window for boosting immunotherapy response in prostate cancer","url":"https://medicalxpress.com/news/2026-10-critical-window-boosting-immunotherapy-response.html","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/9d2efaa5e53b46b7da657fee","kind":"observation","label":"medRxiv Oncology · 2026-10-28 · Dense Longitudinal Multi Omics Reveals Microbial Metabolic Immune Succession During Immune Checkpoint Therapy","url":"https://www.medrxiv.org/content/10.64898/2026.10.24.26366392v1?rss=1","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/bdfa8d13eaef19d8c9955d56","kind":"observation","label":"Biochim Biophys Acta Mol Basis Dis · 2026-10-28 · Beyond pyroptosis: Non-lytic functions of GSDMD in tumor immunity and cancer immunotherapy.","url":"https://doi.org/10.1016/j.bbadis.2026.168519","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}}],"cursor":null,"order":"newest first; we keep the 10 newest receipts for this entity whose own title or URL (the entity graph's subject gate) names it; each says which in match. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":14,"byKind":{"event":1,"claim":3,"co-mentioned":10},"items":[{"id":"sb:p/bbfa1f9b340509bd4c1762f0","kind":"event","label":"regulatory-approval-fda (situation)","role":"named-in","relationKind":"event","members":3},{"id":"sb:p/405c208ddfe91106828ece04","kind":"claim","label":"FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis — reported by two","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/7699bb638b582cbda48dbd38","kind":"claim","label":"Dense Longitudinal Multi Omics Reveals Microbial Metabolic Immune Succession During Immune Checkpoint Therapy — could not check","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/a49b0ff5998717414b274ea7","kind":"claim","label":"Samsung Bioepis Keytruda Biosimilar Matches Original in Phase 1 Trial — single source","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with colorectal cancer (355 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0725cc3ec034d8655a343f00"},{"kind":"relation","label":"co-mentioned with overall survival (187 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c39aa535642ecb09f7fc34bf"},{"kind":"relation","label":"co-mentioned with fda (176 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7452689d97c7c885406e799d"},{"kind":"relation","label":"co-mentioned with lung cancer (166 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/27c8d6ca13365be381edf726"},{"kind":"relation","label":"co-mentioned with china (122 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/eb9e3f039eba6f25b268eee0"},{"kind":"relation","label":"co-mentioned with clinical trial (122 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9484f7f975002eb0509f095e"}],"cursor":"c1.eyJpZCI6InNiOmUvZTIwMDAxYzQ3ZTQwZDRiMTA5ZDVmODM3IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMS0wMlQyMzoyMDozNy41NTIwMjQrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/e20001c47e40d4b109d5f837","mcp":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}","page":"/entity/immunotherapy/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}